



## **News Release**

Source: Patheon Inc.  
Website: [www.patheon.com](http://www.patheon.com)

### **Patheon Inc. Expands Toronto Facility, Creates Dedicated Space for Oral Contraceptives Production**

**RESEARCH TRIANGLE PARK, North Carolina, (April 17, 2009)** – Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, is pleased to announce the expansion of its Toronto manufacturing facility. The expansion adds 10,000 square feet of GMP space dedicated to the production of oral contraceptives with a potential output of 1.3 billion tablets. This includes full-scale commercial production capabilities, including dispensing, granulation, compression, film coating and primary packaging. The new area will utilize abatement technology, which is used for the elimination of solvent emissions and meets projected 2020 Ministry of Environment Standards.

The expansion of dedicated space for the production of oral contraceptives, is a regulatory requirement to sell in many countries, and demonstrates Patheon's continuing commitment to providing the highest level of quality and standards to customers. By providing dedicated space, Patheon will free up manufacturing capacity in the Toronto facility for current and new commercial business and allow for future growth within the Pharmaceutical Development Services area. The newly expanded Toronto site will be a Center of Excellence for Oral Contraceptives under Patheon's proprietary *Quick to Clinic*<sup>™</sup> program.

Terry Novak, President of North America stated, "This expansion positions Patheon to compete on a higher level for contract manufacturing opportunities and claim a larger portion of the global oral contraceptive manufacturing market."

#### **ABOUT PATHEON**

Patheon Inc. (TSX: PTI; [www.patheon.com](http://www.patheon.com)) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic<sup>™</sup> programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable

API. Patheon's integrated network strives to ensure that customer products can be launched with confidence globally.

**Caution Concerning Forward-Looking Statements**

*This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at [www.patheon.com](http://www.patheon.com) or on SEDAR at [www.sedar.com](http://www.sedar.com).*

**Contacts:**

Mr. Wes Wheeler  
President & Chief Executive Officer  
Tel: (919) 226-3200  
Email: [wes.wheeler@patheon.com](mailto:wes.wheeler@patheon.com)

Ms. Jean Treadwell  
Investor Relations  
Tel: (905) 816-8344  
Email: [jean.treadwell@patheon.com](mailto:jean.treadwell@patheon.com)

Mr. Eric Evans  
Chief Financial Officer  
Tel: (919) 226-3200  
Email: [eric.evans@patheon.com](mailto:eric.evans@patheon.com)